New drugs in migraine treatment and prophylaxis: telcagepant and topiramate.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Lancet

• Publication date

  2010-08-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(10)60323-6PMID 20416945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Research Letters

  2012cited by this paper
• Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries

  2010cited by this paper
• The Abnormal Recovery Cycle of Somatosensory Evoked Potential Components in Children with Migraine can be Reversed by Topiramate

  2010cited by this paper
• Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulation

  2010cited by this paper
• Single‐ and Multiple‐Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene‐Related Peptide Receptor Antagonist, in Adults

  2010cited by this paper
• Migraines with and without aura and their response to preventive therapy with topiramate

  2010cited by this paper
• Neurological Mechanisms of Migraine: Potential of the Gap-Junction Modulator Tonabersat in Prevention of Migraine

  2009cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

  2009cited by this paper
• EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

  2009cited by this paper
• Bilateral acute angle closure glaucoma and myopia induced by topiramate.

  2009cited by this paper
• Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta‐Analytic Comparison of Topiramate‐Related Adverse Drug Reactions in Epilepsy and Migraine

  2009cited by this paper
• Elevated Saliva Calcitonin Gene‐Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan

  2009cited by this paper
• Origin of pain in migraine: evidence for peripheral sensitisation.

  2009cited by this paper
• A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study

  2009cited by this paper
• Topiramate for Migraine Prevention in a Naturalistic Setting: Results From an Open Label, Flexible Dose Study

  2009cited by this paper
• Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients.

  2009cited by this paper
• Randomized, controlled trial of telcagepant for the acute treatment of migraine

  2009cited by this paper
• Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.

  2009cited by this paper
• Efficacy and tolerability of topiramate in pediatric migraine.

  2009cited by this paper
• Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.

  2009cited by this paper
• Pathophysiological basis of migraine prophylaxis.

  2009cited by this paper
• Expert Opinion: Adherence to Prophylactic Migraine Medication

  2009cited by this paper
• Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse

  2009cited by this paper
• Resource utilization impact of topiramate for migraine prevention in the managed-care setting*

  2009cited by this paper
• CGRP and CGRP receptor distribution in the human trigeminal ganglion

  2009cited by this paper
• THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF TELCAGEPANT, A NOVEL CALCITONIN GENE RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONIST, IN HEALTHY SUBJECTS AND MIGRAINEURS

  2009cited by this paper
• Program Abstracts

  2009cited by this paper
• Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences

  2009cited by this paper
• The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity

  2009cited by this paper
• Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

  2008cited by this paper
• Effects of Topiramate on Migraine Frequency and Cortical Excitability in Patients with Frequent Migraine

  2008cited by this paper
• Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate

  2008cited by this paper
• International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor

  2008cited by this paper
• Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.

  2008cited by this paper
• A double‐blind, randomized trial of low‐dose topiramate vs propranolol in migraine prophylaxis

  2008cited by this paper
• Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

  2008cited by this paper
• Calcitonin receptor‐like receptor (CLR), receptor activity‐modifying protein 1 (RAMP1), and calcitonin gene‐related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution

  2008cited by this paper
• A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate

  2008cited by this paper
• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

  2008cited by this paper
• CGRP-receptor antagonism in migraine treatment.

  2008cited by this paper
• Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na+ ion channel blockade.

  2008cited by this paper
• Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine

  2008cited by this paper
• Weight change associated with the use of migraine-preventive medications.

  2008cited by this paper
• Anticonvulsants in Migraine Prophylaxis: A Cochrane Review

  2008cited by this paper
• Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• CGRP antagonists: unravelling the role of CGRP in migraine.

  2007cited by this paper
• Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma.

  2007cited by this paper
• Topiramate in the Prophylaxis of Pediatric Migraine: A Double-Blind Placebo-Controlled Trial

  2007cited by this paper
• Inhibition of capsaicin-induced increase in dermal microvascular blood flow by the oral CGRP antagonist, MK-0974

  2007cited by this paper
• Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine

  2007cited by this paper
• Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

  2007cited by this paper
• Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2007cited by this paper
• Cost-Minimization Analysis Comparing Topiramate with Standard Treatments in Migraine Prophylaxis

  2007cited by this paper
• Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).

  2007cited by this paper
• Neurophysiological features of the migrainous brain

  2006cited by this paper
• Suppression of cortical spreading depression in migraine prophylaxis

  2006cited by this paper
• Topiramate Prophylaxis and Response to Triptan Treatment for Acute Migraine

  2006cited by this paper
• Comparison of the Effect of Topiramate and Sodium Valporate in Migraine Prevention: A Randomized Blinded Crossover Study

  2006cited by this paper
• EFNS guideline on the drug treatment of migraine – report of an EFNS task force

  2006cited by this paper
• Topiramate for Migraine Prevention in Adolescents: A Pooled Analysis of Efficacy and Safety

  2006cited by this paper
• Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

  2006cited by this paper
• Cost of disorders of the brain in Europe

  2005cited by this paper
• Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect.

  2005cited by this paper
• Topiramate for Migraine Prevention in Children: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2005cited by this paper
• Low Income and Education Levels May Cause Medication Overuse and Chronicity in Migraine Patients

  2005cited by this paper
• Topiramate inhibits trigeminovascular activation: an intravital microscopy study

  2005cited by this paper
• Neurobiology in primary headaches.

  2005cited by this paper
• Brain Hyperexcitability: The Basis for Antiepileptic Drugs in Migraine Prevention

  2005cited by this paper
• Calcitonin gene–related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine

  2005cited by this paper
• Efficacy of Topiramate and Valproate in Chronic Migraine

  2005cited by this paper
• Topiramate in migraine prophylaxis

  2004cited by this paper
• Topiramate for migraine prevention: a randomized controlled trial.

  2004cited by this paper
• Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

  2004cited by this paper
• Topiramate in Migraine Prevention: Results of a Large Controlled Trial

  2004cited by this paper
• Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study

  2004cited by this paper
• Topiramate in migraine prevention: results of a large controlled trial.

  2004cited by this paper
• Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine

  2004cited by this paper
• Pharmacokinetic Interactions of Topiramate

  2004cited by this paper
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Immunohistochemical Localization of Calcitonin Receptor–Like Receptor and Receptor Activity–Modifying Proteins in the Human Cerebral Vasculature

  2002cited by this paper
• Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.

  2001cited by this paper
• Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study

  2001cited by this paper
• CGRP-RCP, a Novel Protein Required for Signal Transduction at Calcitonin Gene-related Peptide and Adrenomedullin Receptors*

  2000cited by this paper
• Topiramate Modulates GABA‐Evoked Currents in Murine Cortical Neurons by a Nonbenzodiazepine Mechanism

  2000cited by this paper
• Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry.

  2000cited by this paper
• RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

  1998cited by this paper
• Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy.

  1997cited by this paper
• Topiramate: A New Antiepileptic Drug

  1997cited by this paper
• Rizatriptan has central antinociceptive effects against durally evoked responses.

  1997cited by this paper
• The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats

  1993cited by this paper
• Central nervous system binding sites for calcitonin and calcitonin gene-related peptide

  1991cited by this paper
• Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

  1990cited by this paper

• Migraine part 2: evidence-based acute and preventive treatment.

  2025cites this paper
• Understanding the Biological Relationship between Migraine and Depression

  2024cites this paper
• Efficacy and Safety of Atogepant for Preventing Chronic and Episodic Migraines: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Calcitonin-Gene-Related Peptide in Migraine and Tension-Type Headache in Children During Interictal Period

  2024cites this paper
• Calcitonin Gene-Related Peptide Inhibition and Development of Acne and Rosacea.

  2024cites this paper
• The history and rationale of the development of new drugs for migraine treatment

  2023cites this paper
• Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review

  2022cites this paper
• A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond

  2022cites this paper
• Calcitonin gene‐related peptide (CGRP) is a key molecule released in acute migraine attacks—Successful translation of basic science to clinical practice

  2022cites this paper
• Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments

  2021cites this paper
• CGRP and migraine; from bench to bedside.

  2021cites this paper
• Potential Side Effects and Pregnancy

  2021cites this paper
• Vortex-assisted dispersive solid phase microextraction using Fe3O4/FeOOH magnetic nanocomposites for high-performance thin-layer chromatographic determination of zolmitriptan in rabbit plasma samples.

  2021cites this paper
• Migraine therapeutics differentially modulate the CGRP pathway

  2021cites this paper
• Views on migraine pathophysiology: Where does it start?

  2020cites this paper
• Serum CGRP, VIP, and PACAP usefulness in migraine: a case–control study in chronic migraine patients in real clinical practice

  2020cites this paper
• Pd-catalyzed stereoselective tandem ring-opening amination/cyclization of vinyl γ-lactones: access to caprolactam diversity

  2020cites this paper
• Prevalence of Migraine Headache among Secondary School Students in Ramadi City, West of Iraq

  2020cites this paper
• CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior

  2019cites this paper
• Understanding the pathophysiology of migraine pain

  2019cites this paper
• Recognizing the role of CGRP and CGRP receptors in migraine and its treatment

  2019cites this paper
• Role of CGRP in Migraine.

  2019cites this paper
• Distribution of CGRP and CGRP receptor components in the rat brain

  2019cites this paper
• Calcitonin Gene-Related Peptide Antagonists and Therapeutic Antibodies.

  2019cites this paper
• Understanding CGRP and Cardiovascular Risk.

  2019cites this paper
• Rimegepant oral disintegrating tablet for migraine.

  2019cites this paper
• The Presence of Calcitonin Gene-Related Peptide and Its Receptors in Rat, Pig and Human Brain: Species Differences in Calcitonin Gene-Related Peptide Pharmacology

  2019cites this paper
• Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

  2018cites this paper
• Medical Management of Head and Face Pain

  2018cites this paper
• Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?

  2018cites this paper
• Leczenie migreny przewlekłej — zalecenia opracowane przez Grupę Ekspertów Polskiego Towarzystwa Bólów Głowy i Sekcji Badania Bólu Polskiego Towarzystwa Neurologicznego na podstawie międzynarodowych zaleceń i najnowszej literatury

  2018cites this paper
• The CGRP Pathway in Migraine as a Viable Target for Therapies

  2018cites this paper
• CGRP as the target of new migraine therapies — successful translation from bench to clinic

  2018cites this paper
• Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

  2018cites this paper
• A Successful Treatment of Primary Polydipsia with Topiramate

  2018cites this paper
• Blocking CGRP in migraine patients – a review of pros and cons

  2017cites this paper
• The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine

  2017cites this paper
• First study on the peptidergic innervation of the brain superior sagittal sinus in humans.

  2017cites this paper
• Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives

  2017cites this paper
• Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.

  2017cites this paper
• An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide.

  2016cites this paper
• Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography

  2016cites this paper
• Chronic migraine treatment: from OnabotulinumtoxinA onwards

  2016cites this paper
• In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889.

  2016cites this paper
• Neurovascular contributions to migraine: Moving beyond vasodilation.

  2016cites this paper
• CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

  2015cites this paper
• The Journey to Establish CGRP as a Migraine Target: A Retrospective View

  2015cites this paper
• Experimental inflammation following dural application of complete Freund’s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage

  2015cites this paper
• Therapeutic antibodies against CGRP or its receptor.

  2015cites this paper
• New Therapeutic Approaches for the Treatment of Migraine

  2015cites this paper
• New Insights into Diagnostic Biomarkers of Migraine: Biological, Genetic and Radiological

  2015cites this paper
• CGRP antagonists and antibodies for the treatment of migraine

  2015cites this paper
• Drug safety and tolerability in prophylactic migraine treatment

  2015cites this paper
• Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier.

  2015cites this paper
• Meningeal afferent signaling and the pathophysiology of migraine.

  2015cites this paper
• CGRP Mechanism Antagonists and Migraine Management

  2015cites this paper
• Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

  2014cites this paper
• The TRPA1 channel in migraine mechanism and treatment

  2014cites this paper
• Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead

  2014cites this paper
• Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study

  2014cites this paper
• Role of pituitary adenylate cyclase-activating polypeptide (pacap) in the trigeminovascular system: preclinical and clinical results

  2014cites this paper
• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

  2014cites this paper
• REVIEW The TRPA1 channel in migraine mechanism and treatment

  2014cites this paper
• Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds

  2014cites this paper
• CGRP receptor antagonism and migraine therapy.

  2013cites this paper
• Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system.

  2013cites this paper
• Lippia alba (Mill.) N. E. Brown hydroethanolic extract of the leaves is effective in the treatment of migraine in women.

  2013cites this paper
• Distribution of CGRP and CGRP receptor in the trigeminovascular system and CNS

  2013cites this paper
• Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine

  2013cites this paper
• Pearls and pitfalls in neural CGRP immunohistochemistry

  2013cites this paper
• Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults.

  2013cites this paper
• Topiramate for the prophylaxis of episodic migraine in adults.

  2013cites this paper
• Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.

  2013cites this paper
• Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

  2013cites this paper
• Title : The TRPA 1 Channel in Migraine Mechanism and Treatment 1 Abbreviated title : TRPA 1 channel in Migraine

  2013cites this paper
• Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies

  2013influential citation
• Localization of CGRP Receptor Components, CGRP, and Receptor Binding Sites in Human and Rhesus Cerebellar Cortex

  2013cites this paper
• Role of Calcitonin Gene-Related Peptide (CGRP) in Migraine: A Review

  2013cites this paper
• Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients

  2013cites this paper
• Is CGRP a marker for chronic migraine?

  2013cites this paper
• The mechanisms of antihyperalgesic effect of topiramate in a rat model of inflammatory hyperalgesia

  2013cites this paper
• Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method

  2013cites this paper
• Evaluation of the efficacy of caffeine cessation, nortriptyline, and topiramate therapy in vestibular migraine and complex dizziness of unknown etiology.

  2012cites this paper
• Topiramate for the treatment of polydipsia-hyponatremia syndrome.

  2012cites this paper
• Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice

  2012cites this paper
• Response to nimodipine in ultradian bipolar cycling after amygdalohippocampectomy.

  2012cites this paper
• Topiramate: An in Vitro and in Vivo Comparison between the Pharmacokinetic Properties of a Generic (Sincronil) and the Reference (Topamax) Formulation

  2012cites this paper
• Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease

  2012cites this paper
• CGRP antagonists for the treatment of migraine: rationale and clinical data

  2012cites this paper
• Preventive Agents for Migraine: Focus on the Antiepileptic Drugs

  2012cites this paper
• Taking the Negative View of Current Migraine Treatments

  2012cites this paper
• [Gap junctional intercellular communication: a new mechanism in pathophysiology of migraine with aura. Therapeutic applications].

  2012cites this paper
• Basic mechanisms of migraine and its acute treatment.

  2012cites this paper
• A new horizon into the pathobiology, etiology and treatment of migraine.

  2011cites this paper
• Current world literature.

  2011cites this paper
• Neurovascular Pharmacology of Prospective Antimigraine Drugs

  2011cites this paper
• Drug Therapy of Cerebrovascular Disease

  2011cites this paper
• Treatment of migraine: update on new therapies.

  2011cites this paper
• Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.

  2011cites this paper
• Prophylaxis and Treatment of Menstrual Migraine

  2011cites this paper